Carasent - Focus on Investments
2022-03-02 11:00:00
Redeye updates its estimates for 2022 following the Q4 report, and comments on various subjects, ranging from organic growth, net revenue retention, Medrave, Webdoc X/NO, and political risks in the case.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/